Clinical trials: Carcinoma, Basal Cell
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
The primary objective is to confirm the safety of treating multiple BCCs once weekly x 3 weeks in individuals with Basal Cell Nevus Syndrome (BCNS).
- Trial name
- NCT03208296
- Testing
- ASN-002
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ascend Biopharmaceuticals Ltd
Basal Cell Carcinoma
Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma
Collect real world safety data on the use of sonidegib in adult patients with laBCC. Document major safety parameters such as on treatment deaths, adverse events (AEs)/ serious adverse events (SAEs) and discontinuation secondary…
- Trial name
- NISSO (NCT04066504)
- Testing
- sonidegib
- Where
- 47 sites in Germany, Italy and 2 more
- Volunteers
- 323 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Basal Cell Carcinoma
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of nodular basal cell carcinoma.
- Trial name
- NCT00108121
- Testing
- PEP005
- Where
- 10 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Carcinoma, Basal Cell
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
The primary purpose for this multi-center, non-interventional study is to evaluate the duration of response defined as duration from first documented response of complete response (CR) or partial response (PR) until disease…
- Trial name
- NIELS (NCT02674009)
- Testing
- Vismodegib
- Where
- Germany
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype
To evaluate safety and efficacy of AIV001 treatment on low-risk Nonmelanoma Skin Caner of the basal cell carcinoma subtype.
- Conditions
- Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma, Nonmelanoma Skin Cancers
- Trial name
- NMSC (NCT04470726)
- Testing
- AIV001, AIV001 suspension
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- AiViva BioPharma, Inc.
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
CemiplimAb Survivorship Epidemiology
The objectives of the study are: To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic [nodal or distant]) cutaneous…
- Trial name
- CASE (NCT03836105)
- Testing
- cemiplimab
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 287 people
- Sponsor
- Regeneron Pharmaceuticals
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03886181
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Carcinoma, Basal Cell (BCC)
Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
This is a Phase IV, single arm, multicenter study designed to evaluate the efficacy and safety profile of Sonidegib in chinese participants with locally advanced basal cell carcinoma (laBCC) who are not amenable to radiation…
- Trial name
- NCT06880848
- Testing
- Sonidegib Phosphate Capsules
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Jemincare
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC).
- Trial name
- NCT03889912
- Testing
- Cemiplimab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 97 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumor Cancers, Medulloblastoma
An East Asian Study of LDE225
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced…
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT01208831
- Testing
- LDE225
- Where
- 4 sites in Hong Kong, Japan and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult, Solid Tumor
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.
- Conditions
- Solid Tumor, Adult, Solid Tumor, Melanoma, Basal Cell Cancer
- Trial name
- NCT06398418
- Testing
- R-5780
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Rise Therapeutics LLC
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Superficial Basal Cell Carcinoma
Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.
- Trial name
- NCT00189306
- Testing
- Imiquimod 5% cream
- Where
- 18 sites in Australia, New Zealand
- Volunteers
- 169 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Basal Cell Carcinoma
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of superficial basal cell carcinoma.
- Trial name
- NCT00108134
- Testing
- PEP005
- Where
- 9 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Superficial Basal Cell Carcinoma
Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma
The purpose of this study was to compare the efficacy of Photodynamic Therapy (PDT) methyl aminolevulinate (MAL) cream to cryotherapy, in treatment of participants with primary superficial basal cell carcinoma (BCC).
- Trial name
- NCT00469417
- Testing
- Metvix® cream, Hand held liquid nitrogen spray cryotherapy
- Where
- 14 sites in Austria, Belgium and 5 more
- Volunteers
- 120 people
- Sponsor
- Galderma R&D
Skin Lesions, Melanocytic Nevi
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions.
- Conditions
- Skin Lesions, Melanocytic Nevi, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
- Trial name
- LegitHealth PH (NCT07428941)
- Testing
- AI-based medical device for aided diagnosis in dermatological conditions
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- AI Labs Group S.L
Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the…
- Trial name
- NCT00604890
- Testing
- API 31510 3% Topical Cream, API 31510 1.5% Topical Cream
- Where
- 11 sites in United States
- Volunteers
- 186 people
- Sponsor
- BPGbio
Basal Cell Carcinoma
Laser Treatment of Basal Cell Carcinoma
Laser treatment of Basal cell carcinoma
- Trial name
- NCT04936932
- Testing
- 1064 nm long-pulse Nd:YAG laser
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Sciton